Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Works Technologies ABFRA:1BD +5.93%49 Gross Margin % is 74.55% as of Mar. 2026, which is 9% below its 10-year median of 81.66. GuruFocus rates FRA:1BD with a GF Score™ of 49/100 and a GF Value™ of €0.32 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Bio-Works Technologies AB ranks better than 86.19% on this metric.
FRA:1BD's Gross Margin % is ranked better than 86.19% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 52.44
vs FRA:1BD: 75.00
Bio-Works Technologies AB had a gross margin of 74.55% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Bio-Works Technologies AB (FRA:1BD) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bio-Works Technologies AB had a gross margin of 74.55% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bio-Works Technologies AB Gross Margin % Related Terms
Bio-Works Technologies AB Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1BD vs ISRG, BDX, MDLN: Gross Margin % Comparison
For the Medical Instruments & Supplies subindustry, Bio-Works Technologies AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Works Technologies AB Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Works Technologies AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Works Technologies AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bio-Works Technologies AB (FRA:1BD) has a Gross Margin % of 74.55% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Bio-Works Technologies AB and its competitors. This is near median its historical median of 81.66. Over the past decade, Bio-Works Technologies AB's Gross Margin % has ranged from 58.28 to 178.46. According to the industry distribution chart, Bio-Works Technologies AB ranks #111 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 13.8%.
Is Bio-Works Technologies AB's Gross Margin % too high?
Bio-Works Technologies AB's current Gross Margin % of 74.55% is near median its 10-year median of 81.66. Over the past 10 years, this metric has ranged from a low of 58.28 to a high of 178.46. The Medical Devices & Instruments industry median Gross Margin % is 52.44. Bio-Works Technologies AB's value of 74.55% is 42.2% above this industry median. Based on the distribution chart, Bio-Works Technologies AB ranks #111 out of 804 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Works Technologies AB has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Works Technologies AB's Gross Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio-Works Technologies AB ranks #111 out of 804 companies for Gross Margin %. This places Bio-Works Technologies AB in the top 14% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 52.44. Bio-Works Technologies AB's value of 74.55% is 42.2% above this benchmark. Historically, Bio-Works Technologies AB's own Gross Margin % has ranged from 58.28 to 178.46 over the past decade. While the company's 10-year median is 81.66 vs. the industry median of 52.44, Bio-Works Technologies AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.44, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Works Technologies AB's current Gross Margin % of 74.55% is 42.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Bio-Works Technologies AB and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Works Technologies AB's current Gross Margin % is 74.55%, which is near median its own 10-year median of 81.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Works Technologies AB stock overvalued right now?
Based on GuruFocus' analysis, Bio-Works Technologies AB (FRA:1BD) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.32, compared to a current price of €0.29 — trading 10.6% below its estimated fair value. The current Gross Margin % is 74.55%, which is near median its 10-year median of 81.66 and 42.2% above the Medical Devices & Instruments industry median of 52.44. Bio-Works Technologies AB's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Bio-Works Technologies AB (FRA:1BD), the current Gross Margin % is 74.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Works Technologies AB (FRA:1BD) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Works Technologies AB stock appears to be undervalued.
The current stock price of €0.29 is trading 10.6% below its estimated GF Value™ of €0.32.
GuruFocus considers Bio-Works Technologies AB to be Modestly Undervalued.
Key valuation signals for FRA:1BD:
Gross Margin %: 74.55% (near median its 10-year median of 81.66)
GF Value™: €0.32 vs. price of €0.29 (10.6% below fair value)
Industry Position: 42.2% above the Medical Devices & Instruments median (#111 of 804)
No single metric tells the full story. See the FRA:1BD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Works Technologies AB is a Sweden-based life science company which is engaged in designing, developing, manufacturing and supplying products for purification and separation of proteins and other molecules. The product line of the company includes activated resin, immobilized metal-ion affinity chromatography resin, ion exchange chromatography resin, size exclusion chromatography resin and others. The company has also developed affinity chromatography technique, BabyBio Columns, OptiBio glass columns for separating proteins, and protein purification. Bio-Works serves various end users such as academic research laboratories, biopharmaceutical companies, the food and beverage industry and others.
49GF Score
Get the complete analysis for FRA:1BD
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1BD has been successfully added to your 
